Emergent BioSolutions has entered a strategic financial investment agreement with Swiss Rockets to support infrastructure ...

Emergent BioSolutions (EBS) is strengthening relationships with partners across sectors and continuing its commitment to ensuring widespread ...

Emergent BioSolutions is investing in Swiss biotech Rocketvax, inking a deal designed to fuel the preclinical company’s R&D.

Emergent BioSolutions Inc. (NYSE: EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, and Rocketvax Ltd, one of Switzerland’s next ...

As Emergent BioSolutions continues to pawn off manufacturing real estate in its pivot from production specialist to full-time ...

USA-based Emergent BioSolutions (NYSE: EBS) and Swiss vaccines firm Rocketvax have announced an agreement. One part of the ...

Shares of Emergent BioSolutions plunged more than 8% in after-hours trading on Monday after the company reported a steep ...

As part of the investment, Emergent would lead U.S. manufacturing and commercialization efforts for four of Rocketvax’s ...

The company has been selling off its assets after an error caused tens of millions of vaccines to get thrown out during the ...

In a transaction officially set to close later this month, Syngene International Limited, a contract research, development, ...

India's Syngene International on Monday said it has acquired its first biologics facility in the United States from Emergent ...

India's Syngene International on Monday said it has acquired its first biologics facility in the United States from Emergent ...